Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Clearside Biomedical ( (CLSD) ) has shared an update.
On August 28, 2025, Clearside Biomedical received a notice from Nasdaq regarding non-compliance with the Market Value of Listed Securities requirement, giving the company until February 24, 2026, to regain compliance or face potential delisting. Additionally, on August 29, 2025, the company held a special meeting where stockholders approved a proposal for a reverse stock split to address a previous non-compliance issue related to the minimum bid price requirement, aiming to maintain its listing on Nasdaq.
The most recent analyst rating on (CLSD) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.
Spark’s Take on CLSD Stock
According to Spark, TipRanks’ AI Analyst, CLSD is a Underperform.
Clearside Biomedical’s overall stock score is heavily impacted by its poor financial performance and negative corporate events. The bearish technical indicators and poor valuation metrics further contribute to the low score. The company’s strategic uncertainties and risk of delisting present significant risks to investors.
To see Spark’s full report on CLSD stock, click here.
More about Clearside Biomedical
Clearside Biomedical, Inc. operates in the biotechnology industry, focusing on developing therapies to treat eye diseases. The company primarily offers innovative drug delivery solutions targeting the back of the eye, with a market focus on enhancing treatment efficacy and patient outcomes.
Average Trading Volume: 4,546,387
Technical Sentiment Signal: Sell
Current Market Cap: $28.85M
See more data about CLSD stock on TipRanks’ Stock Analysis page.